NewResearch Grade
Retatrutide 40mg
Triple receptor agonist & metabolic support
Retatrutide is a next-generation triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This multi-receptor approach produces potent effects on appetite suppression, glucose regulation, and energy expenditure. This 40mg format is designed for extended research protocols requiring higher dosing flexibility.
- ✓Triple agonist: GIP, GLP-1 & glucagon receptors
- ✓Potent appetite suppression & satiety
- ✓Supports glucose regulation & insulin sensitivity
- ✓Enhanced energy expenditure vs dual agonists
- ✓≥99% purity — HPLC verified
Mechanism of Action
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This tri-agonism produces additive effects on appetite suppression, energy expenditure, and glucose homeostasis. The 40mg vial provides a higher-quantity format for extended research protocols requiring larger sample volumes.
For research and educational purposes only. This information is derived from published preclinical and clinical literature and does not constitute medical advice.